Vi Tran is an associate in the IP Litigation Group based in New York.
Dr. Vi Tran has comprehensive experience in litigation, encompassing pre-suit investigation, drafting of legal documents, discovery, and collaboration with both expert and fact witnesses, as well as advising clients on litigation preparation, strategic patent lifecycle management, and due diligence. She leverages her extensive experience to support life science clients in navigating complex patent issues, including those related to Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) litigations. She also represents clients in parallel patent proceedings such as Inter Partes Reviews (IPRs) and Post Grant Reviews (PGRs) before the Patent Trial and Appeal Board (PTAB).
Dr. Tran earned her Ph.D. in Organic Chemistry from the University of California, Irvine, where she was part of the inaugural class of the Medicinal Chemistry and Pharmacology Gateway Program. Under the guidance of Dr. Keith Woerpel, her doctoral research focused on the stereoelectronic control of nucleophilic addition to five-membered ring oxocarbenium ions, with implications for developing anti-viral and anti-bacterial agents. She completed her B.S. in Chemistry at the California Institute of Technology where she engaged in research under Dr. Jacqueline K. Barton, evaluating modified carbon electrodes for biosensors detecting DNA mismatches, and under Dr. Brian M. Stoltz, where she developed methodologies for palladium-catalyzed formation of carbon-carbon bonds in methylindoles.
Prior to law school, Dr. Tran worked as a research associate in pharmaceutical R&D for a pharmaceutical giant. There, she synthesized and analyzed small molecules for treating neurological dysfunctions and was involved in drafting patent applications for new compounds aimed at treating depression.
Dr. Tran is a named inventor in the following US Patents:
Major Biotech Company
Represented a major biotech company in patent litigation and parallel PTAB proceedings that resulted in a significant jury verdict finding willful infringement.
Leading Medical Technology Company
Represented a leading medical technology company in a patent infringement dispute over metal devices used to prevent bleeding in the GI tract in minimally invasive surgeries.
Major Pharmaceutical and Biotechnology Company
Represented a major pharmaceutical and biotechnology company in a district court litigation and copending Post-Grant Review (PGR) petition relating to a monoclonal antibody therapy.
Major Biopharmaceutical Company
Represented a major biopharmaceutical company in two inter partes reviews (IPRs) of patents relating to peptide therapeutics.
Pharmaceutical Investment Company
Advised a pharmaceutical investment company on its acquisition of a partial royalty interest in a specific antiviral medication from a European anti-infective company.